MARIJUANA SMOKING VS CANNABINOIDS FOR GLAUCOMA THERAPY

REFERENCES

1. Green K. The ocular effects of cannabinoids. In: Zadunaisky JA, Davson
H, eds. Current Topics in Eye Research. Orlando, Fla: Academic Press Inc;
1979;1:175-215.

2. Green K. Current status of basic and clinical marihuana research in
ophthalmology. In: Leopold IH, Burns RP, eds. Symposium on Ocular Therapy.
New York, NY: John Wiley & Sons Inc; 1979;11:37-49.

3. Green K. Marihuana and the eye: a review. J Toxicol Cutan Ocul Toxicol.
1982;1:3-32.

4. Green K. Marijuana effects on intraocular pressure. In: Drance SM,
Neufeld AH, eds. Glaucoma: Applied Pharmacology in Medical Treatment. New
York, NY: Grune & Stratton Inc; 1984:507-526.

5. Mechoulam R, Lander H, Srebnik M, et al. Recent advances in the use of
cannabinoids as therapeutic agents. In: Agurell S, Dewey WL, Willette RE,
eds. The Cannabinoids: Chemical, Pharmacologic and Therapeutic Aspects.
Orlando, Fla: Academic Press Inc; 1984:777-793.

6. Green K, McDonald TF. Ocular toxicology of marijuana: an update. J
Toxicol Cutan Ocul Toxicol. 1987;6:309-334.

7. Green K. History of ophthalmic toxicology. In: Chiou GCY, ed. Ophthalmic
Toxicology. New York, NY: Raven Press; 1992:1-16.

8. Waller CW, Nair RS, McAllister AF, Urbanek B, Turner CE. Marihuana: An
Annotated Bibliography. Vol 2. New York, NY: MacMillan Publishing Co Inc;
1982.

9. Fehr KO, Kalant H, eds. Adverse Health and Behavioral Consequences of
Cannabis Use. Toronto, Ontario: Addictive Research Foundation; 1983.

10. Nahas GG, ed. Marihuana in Science and Medicine. New York, NY: Raven
Press; 1984.

11. Workshop on the Medical Utility of Marijuana: Report to the Director.
Washington, DC: National Institutes of Health; 1997.

12. Nahas GG, Sutin KN, Agurell S, eds. Marijuana and Medicine. Totawa, NJ:
Humana Press. In press.

13. Agurell S, Dewey WL, Willette RE, eds. The Cannabinoids: Chemical,
Pharmacologic and Therapeutic Aspects. Orlando, Fla: Academic Press Inc;
1984.

14. Graham IDP. Cannabis and Health. Orlando, Fla: Academic Press Inc; 1976.

15. Dewey WL. Cannabinoid pharmacology. Pharmacol Rev. 1986;38:151-178.

16. Tashkin DP, Shapiro BJ, Ramanna L, Taplin GV, Lee YE, Harper CE.
Chronic effects of heavy marihuana smoking on pulmonary function in healthy
young males. In: Braude MC, Szara S, eds. The Pharmacology of Marihuana.
New York, NY; Raven Press; 1976:291-295.

17. Rosenkrantz H, Fleischman RW. Effects of cannabis on lungs. In: Nahas
GG, Paton WDM, eds. Marihuana: Biological Effects. Elmsford, NY: Pergamon
Press Inc; 1979:279-299.

18. Dornbush RL, Kokkevi A. The acute effects of various cannabis
substances on cognitive, perceptual, and motor performance in very
long-term hashish users. In: Braude MC, Szara S, eds. The Pharmacology of
Marihuana. New York, NY: Raven Press; 1976:421-427.

19. Marihuana and Health. Washington, DC: National Academy of Sciences,
Institute of Medicine Report; 1982.

20. Murray JB. Marijuana's effects on human cognitive functions,
psychomotor functions, and personality. J Gen Psychol. 1986;113:23-55.

21. Devane WA, Dysarz FA III, Johnson MR, Melvin LS, Howlett AC.
Determination and characterization of a cannabinoid receptor in rat brain.
Mol Pharmacol. 1988;34:605-613.

22. Leon-Carrion J. Mental performance in long-term heavy cannabis: a
preliminary report. Psychol Rep. 1990;67:947-952.

23. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a
peripheral receptor for cannabinoids. Nature. 1993;365:61-65.

24. Howlett AC. Pharmacology of cannabinoid receptors. Ann Rev Pharmacol
Toxicol. 1995;35:607-634.

25. Solowij N. Do cognitive impairments recover following cessation of
cannabis use? Life Sci. 1995;5:2119-2126.

26. Solowij N, Michie PT, Fox AM. Differential impairments of selective
attention due to frequency and duration of cannabis use. Biol Psychiatry.
1995;37:731-739.

27. Fletcher JM, Page JB, Francis DJ, et al. Cognitive correlates of
long-term cannabis use in Costa Rican men. Arch Gen Psychiatry.
1996;53:1051-1057.

28. Pope HG, Yurgelun-Todd D. The residual cognitive effects of heavy
marijuana use in college students. JAMA. 1996;275:521-527.

29. Mechoulam R, Feigenbaum JJ, Lander N, et al. Enantiomeric cannabinoids:
stereospecificity of psychotropic activity. Experientia.1988;44:762-764.

30. Howlett AC, Champion TM, Wilken GH, Mechoulam R. Stereochemical effects
of 11-OH-8-tetrahydrocannabinol-dimethylheptyl to inhibit adenylate cyclase
and bind to the cannabinoid receptor. Neuropharmacology. 1990;29:161-165.

31. D'Ambra TE, Estep KG, Bell MR, et al. Conformationally restrained
analogues of pravadoline: nanomolar potent, enantioselective,
(aminoalkyl)indole agonists of the cannabinoid receptor. J Med Chem.
1992;35:124-135.

32. Compton DR, Gold LH, Ward SJ, Balster RL, Martin BR. Aminoalkylindole
analogs: cannabimimetic activity of a class of compounds structurally
distinct from 9-tetrahydrocannabinol. J Pharmacol Exp Ther.
1992;263:1118-1126.

33. Lynn AB, Herkenham M. Localization of cannabinoid receptors and
nonsaturable high-density cannabinoid binding sites in peripheral tissues
of the rat: implications for receptor-mediated immune modulation by
cannabinoids. J Pharmacol Exp Ther. 1994;268:1612-1613.

34. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain
constituent that binds to the cannabinoid receptor. Science.
1992;258:1946-1959.

35. Fride E, Mechoulam R. Pharmacological activity of the cannabinoid
receptor agonist, anandamide, a brain constituent. Eur J Pharmacol.
1993;231:313-314.

36. Kuster JE, Stevenson JI, Ward SJ, D'Ambra TE, Haycock DA.
Aminoalkylindole binding in rat cerebellum: selective displacement by
natural and synthetic cannabinoids. J Pharmacol Exp Ther. 1993;264:1351-1363.

37. Abadji V, Lin S, Taha G, et al. (R)-methanandamide: a chiral novel
anandamide possessing higher potency and metabolic stability. J Med Chem.
1994;37:1889-1893.

38. Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, Martin BR. The
pharmacological activity of anandamide, a putative endogenous cannabinoid
in mice. J Pharmacol Exp Ther. 1994;270:219-227.

39. Hepler RS, Frank IM, Petrus R. Ocular effects of marijuana smoking. In:
Braude MC, Szara S, eds. The Pharmacology of Marihuana. New York, NY: Raven
Press; 1976:815-824.

40. Perez-Reyes M, Wagner D, Wall ME, Davis KH. Intravenous administration
of cannabinoids on intraocular pressure. In: Braude MC, Szara S, eds. The
Pharmacology of Marihuana. New York, NY: Raven Press; 1976:829-832.

41. Merritt JC, Crawford WJ, Alexander PC, Anduze AL, Gelbart SS. Effect of
marihuana on intraocular and blood pressure in glaucoma. Ophthalmology.
1980;87:222-228.

42. Jones RT, Benowitz N. The 30-day trip: clinical studies of cannabis
tolerance and dependence. In: Braude MC, Szara S, eds. The Pharmacology of
Marihuana. New York, NY: Raven Press; 1976:627-642.

43. Dawson WW, Jiminez-Antillon CF, Perez JM, Zeskind JA. Marihuana and
vision after ten years' use in Costa Rica. Invest Ophthalmol.
1977;16:689-699.

44. Hepler RS, Frank IM, Ungerleider JT. Pupillary constriction after
marijuana smoking. Am J Ophthalmol. 1972;74:1185-1190.

45. Brown B, Adams M, Halgerstrom-Portnoy G, Jones RT, Flom MC. Pupil size
after use of marijuana and alcohol. Am J Ophthalmol. 1977;83:350-354.

46. Hepler RS, Petrus R. Experiences with administration of marihuana to
glaucoma patients. In: Cohen S, Stillman RC, eds. The Therapeutic Potential
of Marihuana. New York, NY: Plenum Publishing Corp; 1976:63-75.

47. Green K, Bowman KA. Effect of marihuana derivatives on intraocular
pressure. In: Braude MC, Szara S, eds. The Pharmacology of Marihuana. New
York, NY: Raven Press; 1976:803-813.

48. Green K, Symonds CM, Oliver NW, Elijah RD. Intraocular pressure
following systemic administration of cannabinoids. Curr Eye Res.
1982-1983;2:247-253.

49. El-Sohly MA, Harland EC, Benigni DA, Waller CW. Cannabinoids in
glaucoma, II: the effect of different cannabinoids on intraocular pressure
of the rabbit. Curr Eye Res. 1984;3:841-850.

50. Waller CW, Benigni DA, Harland EC, Bedford JA, Murphy JC, El-Sohly MA.
Cannabinoids in glaucoma, III: the effects of different cannabinoids on
intraocular pressure in the monkey. In: Agurell S, Dewey WL, Willette RE,
eds. The Cannabinoids: Chemical, Pharmacologic and Therapeutic Aspects.
Orlando, Fla: Academic Press Inc; 1984:871-880.

51. Green K, Wynn H, Bowman K. A comparison of topical cannabinoids on
intraocular pressure. Exp Eye Res. 1978;27:239-246.

52. Howes JF. Antiglaucoma effects of topically and orally administered
cannabinoids. In: Agurell S, Dewey WL, Willette RE, eds. The Cannabinoids:
Chemical, Pharmacologic and Therapeutic Aspects. Orlando, Fla: Academic
Press Inc; 1984:881-890.

53. Merritt JC, Whitaker R, Page CJ, et al. Topical
delta-8-tetrahydrocannabinol as a potential glaucoma agent. Glaucoma.
1982;4:253-255.

54. Merritt JC, Peiffer RL, McKinnon SM, Stapleton SS, Goodwin T, Risco JM.
Topical delta-9-tetrahydrocannabinol on intraocular pressure in dogs.
Glaucoma. 1981;3:13-16.

55. Green K, Bigger JF, Kim L, Bowman K. Cannabinoid penetration and
chronic effects in the eye. Exp Eye Res. 1977;24:197-205.

56. Green K, Sobel RE, Fineberg E, Wynn HR, Bowman KA. Subchronic ocular
and systemic toxicity of topically applied delta-9-tetrahydrocannabinol.
Ann Ophthalmol. 1981;13:1219-1222.

57. Merritt JC, Olsen JL, Armstrong JR, McKinnon SM. Topical
delta-9-tetrahydrocannabinol in humans. J Pharm Pharmacol. 1981;33:40-41.

58. Merritt JC, Perry DD, Russell DN, Jones BF. Topical
delta-9-tetrahydrocannabinol and aqueous dynamics in glaucoma. J Clin
Pharmacol. 1981;21(suppl 8-9):467S-471S.

59. Green K, Roth M. Ocular effects of topical administration of
delta-9-tetrahydrocannabinol in man. Arch Ophthalmol. 1982;100:265-267.

60. Jay WM, Green K. Multiple-drop study of topically applied 1%
9-tetrahydrocannabinol in human eyes. Arch Ophthalmol. 1983;101:591-593.

61. Beilin M, Aviv H, Friedman D, et al. HU2 11, a novel synthetic,
non-psychotropic cannabinoid with ocular hypotensive activity [abstract].
Invest Ophthalmol Vis Sci. 1993;34(suppl):1113.

62. Sugrue MF. New approaches to antiglaucoma therapy. J Med Chem.
1997;40:2793-2809.

63. Lucas VS, Laszlo J. delta-9-tetrahydrocannabinol for refractory
vomiting induced by cancer chemotherapy. JAMA. 1980;243:1241-1243.

64. Poster DS, Penta JS, Bruno S, Macdonald JS.
delta-9-tetrahydrocannabinol in clinical oncology. JAMA. 1981;245:2047-2051.

65. Schwartz RH, Voth EA, Sheridan MJ. Marijuana to prevent nausea and
vomiting in cancer patients: a survey of clinical oncologists. South Med J.
1997;90:167-172.

66. Allen T. Tetrahydrocannabinol and chemotherapy [letter]. N Engl J Med.
1976;294:168.

67. Turner CE, El-Sohly MA, Boeren EG. Constituents of Cannabis sativa (L),
XVII: a review of the natural constituents. J Nat Prod. 1980;43:169-234.

68. Doorenbos NJ, Fetterman PS, Quimby MW, Turner CE. Cultivation,
extraction and analysis of Cannabis sativa (L). Ann N Y Acad Sci.
1971;191:3-14.

69. Ross SA, El-Sohly MA. Constituents of Cannabis sativa L, XXVIII: a
review of the natural constituents: 1980-1984. Zagazig J Pharm Sci.
1995;4:1-10.

70. Green K, Kim K. Acute dose response of intraocular pressure to topical
and oral cannabinoids. Proc Soc Exp Biol Med. 1977;154:228-231.

71. Mechoulam R, Lander N, Varkony TH, et al. Stereochemical requirements
for cannabinoid activity. J Med Sci. 1980;23:1068-1072.

72. Newell FW, Stark P, Jay WM, Schanzlin DJ. Nabilone: a pressure-reducing
synthetic benzopyran in open-angle glaucoma. Ophthalmology. 1979;86:156-160.

73. Lemberger L. Potential therapeutic usefulness of marijuana. Ann Rev
Pharmacol Toxicol. 1980;20:151-172.

74. Razdan RK. Structure-activity relationships in cannabinoids. Pharmacol
Rev. 1986;38:75-149.

75. Sugrue MF, Funk HA, Leonard Y, O'Neill-Davis L, Labelle M. The ocular
hypotensive effects of synthetic cannabinoids [abstract]. Invest Ophthalmol
Vis Sci. 1996;37(suppl):831.

76. Pate DW, Jarvinen K, Urtti A, Harho P, Jarvinen T.
Arachidonylethanolamide decreases intraocular pressure in normotensive
rabbits. Curr Eye Res. 1995;14:791-797.

77. Pate DW, Jarvinen K, Urtti A, et al. Effects of topical anandamides on
intraocular pressure in normotensive rabbits. Life Sci. 1996;58:1849-1860.

78. Hodges LC, Reggio PH, Green K. Evidence against cannabinoid receptor
involvement in intraocular pressure: effects of cannabinoids in rabbits.
Ophthalmic Res. 1997;29:1-5.

79. Hollister LE, Gillespie HK. Delta-8- and delta-9-tetrahydrocannabinol:
comparison in man by oral and intravenous administration. Clin Pharm Ther.
1973;14:353-357.

80. Wall ME, Brine DR, Perez-Reyes M. Metabolism of cannabinoids in man.
In: Braude MC, Szara S, eds. The Pharmacology of Marihuana. New York, NY:
Raven Press; 1976:93-113.

81. Green K. Marijuana and intraocular pressure: possible mechanisms of
action. In: Nahas GG, Sutin KN, Agurell S, eds. Marijuana and Medicine.
Totawa, NJ: Humana Press. In press.

82. Voth EA, Schwartz RH. Medicinal applications of
delta-9-tetrahydrocannabinol and marijuana. Ann Intern Med. 1997;126:791-798.

Checked-by: Richard Lake